NCT07287202: Safety, Tolerability, and Pharmacokinetics of SVG103 (Paxalisib) in Focal Cortical Dysplasia Type II (FCD-II), Tuberous Sclerosis Complex (TSC) or Hemimegalencephaly (HME)
- State
- Under way
- Phase
- Phase 1 and Phase 2
- People
- 12 planned
- Started
- 14 Jul 2026
- Primary completion
- Feb 2027
- Arms
- Arm1, Arm2
- Results
- None posted
- 17 Dec 2025: Trial registered
- 14 Jul 2026: Trial started